Irreversible Electroporation of Unresectable Liver Tumors

  • STATUS
    Recruiting
  • End date
    Mar 30, 2025
  • participants needed
    15
  • sponsor
    Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Updated on 19 February 2024
cancer
metastasis
liver tumor
hepatoma
biliary tract cancer
irreversible electroporation

Summary

The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.

Description

Patients can be included in the study if they have one or more malignant liver tumors unsuitable for resection and thermal ablation (due to proximity of major vessels or bile duct) or other established liver directed therapies.

Prior to inclusion all potential participant will be evaluated by the local multidisciplinary team, to insure fulfillment of the above-mentioned criteria. In general, the included patient will have tumors with <1 cm of margin to major hepatic vessels or bile ducts, thereby not allowing for conventional treatments because of risk of i.e. hemorrhage, biliary tract damage, liver failure or ineffective ablation due to heat sink.

IRE will be done under general anesthesia as an in-patient procedure. Patients will be observed for at least 24 hours after IRE.

Patients will attend CT scans 1, 3, 6, 9, 12, 18, 24, 36, 48 and 60 months post-IRE according to national guidelines (for follow-up after radiofrequency ablation (RFA)). Patients will attend the out-patient clinic after 1, 3, 6, 9, 12, 18 and 24 months. During the follow-up period, patients will be asked to fill out electronic forms monitoring pain, quality of life and nutritional status. After 24 months the patients will only be followed with CT scans in accordance with the mentioned schedule. Data collection for scientific purposes will stop when the last included patient has been followed for at least 24 months or when the study period concludes.

In case of multiple liver tumors, where a conventional treatment approach is not possible due to a single lesion being too close to major vessels or bile ducts, IRE may be used in conjunction to conventional therapy.

Details
Condition Bile duct carcinoma, Adenocarcinoma, Adenocarcinoma, Biliary neoplasm, HEPATIC NEOPLASM, liver cancer, HEPATOCELLULAR CARCINOMA, Liver Metastases, liver cancer
Age 18-100 years
Treatment Irreversible electroporation
Clinical Study IdentifierNCT04404647
SponsorOle Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Primary or secondary cancer of the liver
Largest tumor diameter 5 cm in any plane
Tumor must be deemed as unresectable and unsuitable for other established curative liver directed therapies
Treatment must be given with curative intent
Patients must be able to give informed consent

Exclusion Criteria

Radiological signs of synchronous intra- or extrahepatic disease, unless curative intended therapy is planned
Tumor is inaccessible e.g. due to venous dilation etc. (assessed with preoperative ultrasound)
American Society of Anesthesiologists (ASA) score >3
Eastern Cooperative Oncology Group (ECOG) performance status >2
Child-Pugh class C
International Normalized Ratio (INR)>1.5
Pregnancy
Persistent atrial fibrillation
Implanted electronic devices e.g. cardiac pacemakers or other electrostimulators
Metal stents or other metallic objects near the ablation zone (unless the stent can be replaced with a plastic stent prior to IRE)
Severe allergies to anesthetic agent, paralytic agent or any of the equipment used during treatment
Patient is referred from a hospital outside of Denmark
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.